Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 12138083 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Morley SJ, Naegele S (2002) Phosphorylation of eukaryotic initiation factor (eIF) 4E is not required for de novo protein synthesis following recovery from hypertonic stress in human kidney cells. J Biol Chem 277, 32855-9 12138083
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S65-p - 4E-BP1 (human) ▲
Orthologous residues
4E‑BP1 (human): S65‑p, 4E‑BP1 (mouse): S64‑p, 4E‑BP1 (rat): S64‑p, 4E‑BP1 (fruit fly): S65‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
hypertonic buffer decrease

S209-p - eIF4E (human) ▲
Orthologous residues
eIF4E (human): S209‑p, eIF4E (mouse): S209‑p, eIF4E (rat): S209‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
CGP57380 serum inhibit treatment-induced increase
CGP57380 decrease
hypertonic buffer decrease

S1147-p - eIF4G (human) ▲
Orthologous residues
eIF4G (human): S1147‑p, eIF4G iso1 (human): S1148‑p, eIF4G iso3 (human): S1107‑p, eIF4G (mouse): S1149‑p, eIF4G iso2 (mouse): S1135‑p, eIF4G (rat): S1147‑p, eIF4G (rabbit): S950‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
CGP57380 serum no effect upon treatment-induced increase
CGP57380 no change compared to control
hypertonic buffer decrease

T180-p - p38-alpha (human) ▲
Orthologous residues
p38‑alpha (human): T180‑p, p38‑alpha iso2 (human): T180‑p, p38‑alpha (mouse): T180‑p, p38‑alpha (rat): T180‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
hypertonic buffer increase

Y182-p - p38-alpha (human) ▲
Orthologous residues
p38‑alpha (human): Y182‑p, p38‑alpha iso2 (human): Y182‑p, p38‑alpha (mouse): Y182‑p, p38‑alpha (rat): Y182‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
hypertonic buffer increase

T444-p - p70S6K (human) ▲
Orthologous residues
p70S6K (human): T444‑p, p70S6K iso2 (human): T421‑p, p70S6K (mouse): T444‑p, p70S6K (rat): T444‑p, p70S6K iso2 (rat): T421‑p, p70S6K (fruit fly): ‑
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
hypertonic buffer decrease

S447-p - p70S6K (human) ▲
Orthologous residues
p70S6K (human): S447‑p, p70S6K iso2 (human): S424‑p, p70S6K (mouse): S447‑p, p70S6K (rat): S447‑p, p70S6K iso2 (rat): S424‑p, p70S6K (fruit fly): ‑
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
hypertonic buffer decrease


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.